

# COVINGTON & BURLING

1201 PENNSYLVANIA AVENUE NW  
WASHINGTON, DC 20004-2401  
TEL 202.662.6000  
FAX 202.662.6291  
WWW.COV.COM

WASHINGTON  
NEW YORK  
SAN FRANCISCO  
LONDON  
BRUSSELS

1781 OK MAR 12 7:30  
PETER BARTON HUTT  
TEL 202.662.5522  
FAX 202.778.5522  
PHUTT@COV.COM

March 10, 2004

Dockets Management Branch (HFA-305)  
Food and Drug Administration  
Room 1061  
5630 Fishers Lane  
Rockville, Maryland 20857

Re: Petition for Reconsideration and Stay of Action  
Final Monograph for OTC Antiperspirant Drugs  
68 Fed. Reg. 34273 (June 9, 2003)  
Docket No. 78N-0064

Revlon, Inc., submits this additional information, as requested by the FDA Division of OTC Drugs, in support of its Petition for Reconsideration and Stay of Action, dated July 7, 2003, with respect to this matter. The active ingredients in the two studies submitted by Revlon on January 5, 2004 to this Docket are as follows:

HRT Study No. 03-121791-112 (July 30, 2003): Aluminum  
Zirconium tetrachlorohydrate-glycine, concentration 19.76 percent.

HRT Study No. 03-121794-112 (September 24, 2003): Aluminum  
Zirconium tetrachlorohydrate-glycine, concentration 19.51  
percent.



Peter Barton Hutt  
Counsel for Revlon, Inc.

cc: Matthew R. Holman (HFD-560)

78N-0064

SUP 5